Studies utilizing RIP1 kinase inhibitors and genetically RIP1 kinase-dead mice have highlighted the significance of RIP1 kinase activity in multiple dietary models of MASLD. Here, RIPK1 is linked to metabolic dysfunction-associated steatotic liver disease.